Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life threatening cutaneous reactions that are most commonly caused by exposure to medications. This review assesses the efficacy and safety of cyclosporine therapy for SJS, TEN, and SJS/TEN overlap. A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. Five case series and one meta-analysis were analyzed. From review of the existing literature, cyclosporine appears to not only have a mortality benefit in the treatment of SJS/TEN, but also a relatively safe side effect profile. tion of CD4+ and CD8+ T cells, which subsequently inhibits the secretion of granulysin, granzyme, and perforin. Nuclear factor-κB is then inhibited, thus halting apoptosis and stopping the disease process (Schneider & Cohen, 2017; Stern & Divito, 2017) . Inhibition of lymphokine production is rapid. Introduction of cyclosporine to cloned cytotoxic T cell has been observed to inhibit lymphokine production in as soon as 36 hr (Herold, Lancki, Moldwin, & Fitch, 1986) . Theoretically, administration of cyclosporine in the setting of SJS/TEN reduces cytotoxicity, prevents apoptosis and inhibits the continued effects driving SJS/TEN pathogenesis. The purpose of this review is to assess the efficacy and safety of cyclosporine as adjunctive therapy in SJS/TEN.
| BACKGROUND
Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are rare but life-threatening cutaneous reactions that generally occur in response to a medication. SJS and TEN can manifest as various types of bullae, but usually possess a positive Nikolsky sign-the upper layers of the skin slip away from the lower layers when the skin is rubbed. The distinction of SJS or TEN is determined by the degree of body surface area (BSA) involvement; less than 10% BSA involvement is indicative of SJS, and over 30% BSA involvement is indicative of TEN. BSA involvement between 10% and 30% is described as SJS/TEN overlap. The hallmark feature of both SJS and TEN is mucosal involvement, with oral sites more commonly involved. Disease severity and prognosis can be determined by utilizing the severity-of-illness score for TEN (SCORTEN), which identifies seven risk factors for mortality.
The most important intervention is early withdrawal of the offending medication(s) and airway assessment. Supportive care includes monitoring of renal function and fluid status, along with assuring adequate nutrition, skin integrity, pain control, and prevention of infection. Treatment in an intensive care unit or burn unit may be required. Other adjunctive therapies that have been described in small studies or case reports include immune-modulating agents such as systemic corticosteroids, intravenous immunoglobulin (IVIg), etanercept, infliximab, thalidomide, and cyclosporine.
While the exact mechanism of SJS and TEN remains unclear, perforin, granzyme B, and granulysin are considered "key mediators" in its pathogenesis (Schneider & Cohen, 2017) . Studies have demonstrated that by inhibiting these mediators and reducing their expression, cytotoxicity is diminished (Chung, Wang, & Dao, 2016; Nassif et al., 2002) . For this reason, cyclosporine has been used as an adjunctive therapy in the treatment of SJS/TEN. Cyclosporine inhibits the early phases of activation of CD4+ and CD8+ T cells, which subsequently inhibits the secretion of granulysin, granzyme, and perforin. Nuclear factor-κB is then inhibited, thus halting apoptosis and stopping the disease process (Schneider & Cohen, 2017; Stern & Divito, 2017) . Inhibition of lymphokine production is rapid. Introduction of cyclosporine to cloned cytotoxic T cell has been observed to inhibit lymphokine production in as soon as 36 hr (Herold, Lancki, Moldwin, & Fitch, 1986) . Theoretically, administration of cyclosporine in the setting of SJS/TEN reduces cytotoxicity, prevents apoptosis and inhibits the continued effects driving SJS/TEN pathogenesis. The purpose of this review is to assess the efficacy and safety of cyclosporine as adjunctive therapy in SJS/TEN.
| LITERATURE REVIEW
A literature review was conducted in PubMed using the MeSH terms TEN, SJS, and cyclosporine. The resulting articles that were published in English were reviewed. A total of 56 articles populated using the specific MeSH terms, 14 review articles, 6 case series, 2 guidelines, and 1 meta-analysis. Articles that did not specifically pertain to systemic cyclosporine treatment in TEN or those which evaluated pediatric patients were excluded. Review articles were utilized for background information.
| EFFICACY
Although there is a lack of randomized controlled clinical trials, cyclosporine has shown efficacy in various cohort studies (Table 1) (Singh et al., 2013) . The SCORTEN system predicted that 1.11 patients treated with cyclosporine were expected to die, with a mean predicted mortality rate of 10.16% (SD 9.5), but no deaths were observed. In patients treated with corticosteroids (intravenous dexamethasone followed by oral prednisolone ≥1 mg/kg/day), the SCOR-TEN system determined that 0.51 patients were expected to die with mean predicted mortality rate of 8.55% (SD 13.10), but two deaths were observed, indicating a mortality benefit in those treated with cyclosporine as compared to corticosteroids. However, it should be noted that both studies compared results to historical data, and lack a true comparator arm.
Two retrospective cohort studies also observed favorable outcomes in patients treated with cyclosporine. Kirchhof et al. (2014) evaluated 64 patients who were diagnosed with SJS, TEN, or SJS/TEN overlap. Thirty-seven patients were treated with IVIG (1 g/kg/day) and seventeen patients were treated with cyclosporine, and predicted severity-of-illness score for TEN mortality was compared with observed mortality. Despite an expected mortality rate of 20.8% in the IVIg group, the observed mortality rate was 29.7%. Whereas, in the cyclosporine group the expected mortality rate was 14.1% and the observed mortality rate was 5.9%. The standardized mortality ratio (SMR; sum of observed deaths/sum of expected deaths), for IVIg-treated patients was 1.43, whereas the SMR for patients treated with cyclosporine was 0.42. The authors concluded that the calculated SMR benefit, along with lesser observed versus predicted SCORTEN deaths, suggests a survival benefit to cyclosporine use in SJS/TEN patients. Another retrospective cohort compared outcomes of 44 patients with SJS, TEN, or SJS/TEN overlap who were treated with either oral cyclosporine (n = 24) or supportive care (n = 20) (Lee et al., 2017) . The SCORTEN system predicted 7.2 deaths in the cyclosporine group versus 5.9 deaths in the supportive care group. The observed mortality in those treated with cyclosporine was 3 deaths, as compared with 6 deaths in the supportive care group (SMR = 0.42 and 1.02, respectively). The study also reported that there were no differences with respect to the development of renal failure requiring dialysis, bacteremia, and mechanical ventilation between those who received cyclosporine and those who did not.
González-Herrada et al. (2017) took advantage of a "natural
experiment" by comparing two reference burn units in Madrid; one that utilizes cyclosporine in SJS/TEN treatment, whereas the other does not. Of 49 patients treated with cyclosporine, 11.8 were expected to die based on their SCORTEN score, however only five deaths were observed. Twenty-two patients were treated with noncyclosporine therapies, 6.4 deaths (29.1%) were expected to occur, whereas seven deaths (31.8%) were observed. The resulting SMR was 0.42 for cyclosporine and 1.09 for non-cyclosporine therapies. Lastly, a meta-analysis of 96 studies comprising 3,248 SJS/TEN patients who were managed with supportive care, or a variety of other treatments including glucocorticoids, IVIg, cyclosporine, plasmapheresis, thalidomide, cyclophosphamide, hemo-perfusion, tumor necrosis factor inhibitors, or granulocyte colony-stimulating factor (Table 2) . Glucocorticoids and cyclosporine were the only two agents associated with promising survival benefit (Zimmermann et al., 2017) .
| DOSE AND DURATION
For the indication of solid organ transplant (SOT), cyclosporine is dosed at 15 mg/kg/day orally or 5-6 mg/kg IV daily, with the first dose 4-12 hr prior to transplant and continued once daily for 1-2 weeks and is then tapered by 5% per week to a maintenance dose. The maintenance dose is 5-10 mg/kg/day orally and is continued for as long as the patient responds and tolerates treatment (Perrigo Company, 2017) . Optimal dosing of cyclosporine for TEN is unclear. Various studies have utilized different dosing approaches. In an open pilot study, oral cyclosporine was dosed to patients in a 1-month taper: 1.5 mg/kg twice a day for 10 days, followed by 1 mg/kg twice a day for 10 days, then 0.5 mg/kg twice a day for 10 days (Valeyrie-Allanore et al., 2010) . A retrospective cohort reported an average cyclosporine dose of 3-5 mg/kg/day either orally or intravenously for an average of 7 days (Kirchhof et al., 2014) .
Another study assessed 3 mg/kg/day of cyclosporine oral solution (in three divided doses) for 7 days, followed by 2 mg/kg (in two divided doses) for 7 days (Singh et al., 2013) . Not all studies detailed how or if cyclosporine doses were divided, however for the indication of SOT, cyclosporine is typically divided into two equal doses per day (Enderby & Keller, 2015) . As discussed, studies have opted to use various dosing schemes for the indication of SJS/TEN, but commonly, 3 mg/kg/day is the starting dose, divided twice daily, with an average treatment duration of 14 days. Dose tapering over 1 month has been described in order to prevent rebound of skin lesions (ValeyrieAllanore et al., 2010).
| SAFETY
Studies assessing cyclosporine efficacy in SJS or TEN are small in nature and did not evaluate safety end points. The largest prospective study evaluating cyclosporine efficacy for SJS/TEN enrolled 29 patients. Of the 29, three stopped treatment prematurely because of adverse events, which consisted of acute hallucinations suspected to be related to reversible posterior leukoencephalopathy (n = 1), transitory neutropenia (n = 1), and severe infection (nosocomial pneumopathy, n = 1). Other adverse events that occurred were hypertension (systolic ≥160 mmHg and diastolic ≥100 mmHg, n = 3), slightly reduced renal function (creatinine level between 120% and 150% of initial value, n = 2) and sensitive neuropathy (n = 1; Valeyrie-Allanore et al., 2010) . In a retrospective cohort, 9 out of 24 patients that received cyclosporine stopped treatment early due adverse effects including worsening renal function, n = 6, suspected myotoxicity, n = 1, and patient's preference, n = 2 (Lee et al., 2017) .
Larger studies comparing azathioprine to cyclosporine in SOT patients reported increased incidence of renal dysfunction (33%), hypertension (31%), hirsutism (31%), tremor (36%), gingival hyperplasia (10%), and hepatotoxicity (5%) Patients can remain on the reduced dose for 6 months up to 1 year, if not lifelong (Enderby & Keller, 2015) . Patients with SJS/TEN are at a reduced risk for developing these adverse effects, as treatment duration is usually less than 1 month.
It should be noted that studies assessing the efficacy of cyclosporine in TEN excluded patients with a creatinine clearance <60 ml/ min, hypertension (systolic ≥160 mmHg and or diastolic ≥100 mmHg), a previous intolerance to cyclosporine, pregnancy, uncontrolled diabetes mellitus, severe infection, malignancy, or immunodeficiency (Lee et al., 2017; Nassif et al., 2002; Valeyrie-Allanore et al., 2010) . Studies assessing cyclosporine efficacy and safety in rheumatoid and psoriatic arthritis also excluded patients with uncontrolled hypertension, significant renal disease at baseline and four patients were removed from the study because of serum creatinine increase (Karanikolas et al., 2011; Miranda, 2004; Tugwell et al., 1995) . Rates of nephrotoxicity in renal, cardiac and liver transplant patients have been reported to be 25%, 38%, and 37%, respectively and 150% of initial value, and therefore had their dosage tapered by 25% at days 10 and 13 (Valeyrie-Allanore et al., 2010) . Other studies have either used similar exclusion criteria (creatinine ≥150% or DBP > 110 mmHg) or have excluded patients on long term renal replacement therapy (Lee et al., 2017; Singh et al., 2013) . It is worth noting that initial oral cyclosporine dosing for transplant rejection prophylaxis is much higher than doses described for treatment of SJS/TEN (15 mg/kg/day vs. 3 mg/kg/day). However, small studies evaluating cyclosporine use in SJS/TEN were not powered to report large-scale adverse effect outcomes, so extrapolation from organ transplant data are useful. 
| MALIGNANCY
Cyclosporine is an immunosuppressant and may place patients at increased risk for developing lymphomas and other malignancies, particularly those related to the skin. Historical studies comparing azathioprine to cyclosporine in transplanted patients demonstrated development of leukopenia and lymphoma in 0.6% and 0.9% of cyclosporine-treated patients, respectively. Patients receiving cyclosporine for transplant can be kept on maintenance immunosuppression for over a year, depending on response and tolerability. In patients with psoriasis being treated with cyclosporine, squamous cell, and basal cell carcinomas were reported in 0.9% and 0.4% of patients.
Patients usually are not stabilized in psoriasis treatment until 12-16 weeks, but likely require 3-4 months of treatment before experiencing optimal control (Menter et al., 2009 
| CONCLUSION
Despite a lack of randomized control trials for the indication, cyclosporine at a dose of 3 mg/kg/day orally or via nasogastric administration appears to have a mortality benefit in the treatment of SJS/TEN.
Efficacy data are limited to retrospective trials, however, due to the relative rarity of the condition, large, randomized control trials may not be realistic. Cyclosporine should be avoided in SJS/TEN patients with baseline renal insufficiency, and may require dose reduction or discontinuation in patients who experience elevations in serum creatinine during treatment. Because of the relative short duration of treatment for SJS/TEN, the concern for malignancy development or infection is low.
